Forte Biosciences price target raised to $6 from $4 at Brookline

Brookline analyst Kumaraguru Raja raised the firm’s price target on Forte Biosciences to $6 from $4 and keeps a Buy rating on the shares following the Q2 report. The company’s FB102 is advancing in celiac disease, the analyst tells investors in a research note. The firm updated its model to include Forte’s potential in celiac disease. It believes there is a significant unmet need in treating celiac disease with no treatments approved.